Truveris

Almost every employer in America signs a pharmacy benefits contract it cannot actually read. The terms are dense, the pricing formulas are layered, and the party managing the drug spend - the pharmacy benefit manager, or PBM - is often the same party that profits from the gaps in it. Truveris was built, in 2009, to change that arrangement.

The company is a healthcare technology firm focused on a single, unglamorous problem: making pharmacy benefits measurable. It runs a competitive marketplace that puts more than 60 PBMs into a structured bidding process, then analyzes 100% of the resulting pharmacy claims to check whether the winning vendor actually delivered what the contract promised. When it doesn't, Truveris flags the discrepancy.

Crucially, Truveris does not sell drugs and is not a PBM itself. That vendor-neutral stance is the whole pitch - it can benchmark and audit the middlemen precisely because it is not one of them.

The result is a business that sits between buyers and the pharmacy supply chain, translating opaque contracts into numbers a benefits consultant can defend to a client. Truveris says the average client sees roughly a 20% improvement on pharmacy contract costs when running procurement and oversight through its platform.

That figure is the company's north star - and, effectively, its entire value proposition.

Truveris sells to three overlapping audiences. First, employers and plan sponsors - the organizations footing the pharmacy bill, from mid-market companies to public entities. In 2022 the State of Minnesota selected Truveris to help optimize its statewide pharmacy benefits program, a signal that the platform had moved beyond private-sector deals.

Second, benefits consultants and brokerages, who deploy Truveris across their client books. As one benefits consultant put it bluntly: "I've put Truveris in place on nearly all of my clients." For a broker, the platform is a way to prove, with claim-level data, that the PBM they recommended is performing.

Third, the PBMs themselves, more than 60 of which participate in the Truveris Marketplace to bid competitively for contracts.

The pharmacy benefits market is crowded with incumbent PBMs and a wave of transparency-focused challengers. Truveris's differentiation is structural, not cosmetic.

Competitors and alternatives range from giant PBMs like Express Scripts to newer transparent players such as Capital Rx, SmithRx, Scripta Insights, Waltz Health and LucyRx. Most of them, in one form or another, are in the business of managing or dispensing pharmacy benefits. Truveris is not. It stays deliberately independent - it benchmarks, procures against and audits PBMs on behalf of the buyer.

That independence is what lets a broker use Truveris data as objective evidence rather than a vendor's marketing.